Key Highlights
- hVIVO plc (LSE:HVO) gained 6.09% on 7 October 2026.
- The contracted order book more than doubled in the first half of 2026.
- Management expects H2 2026 Revenue to roughly double H1, with full-year revenue of about £47 million.
- The group expects positive adjusted EBITDA in H2 2026 and only a low single-digit adjusted EBITDA loss for the full year.
hVIVO Shares Move Higher on 7 October 2026
hVIVO plc (LSE:HVO), the world leader in human challenge Clinical Trials and a full-service early-phase clinical development partner, rose 6.09% on 7 October 2026. The AIM-quoted company, a constituent of the FTSE AIM All-Share Index, has been working through a difficult period for the contract research industry and is now guiding to a sharp second-half recovery.
Human challenge trials involve deliberately exposing healthy volunteers to a pathogen under controlled conditions to test vaccines and antivirals. hVIVO has built a global reputation in this niche and has broadened its offering through acquisitions.
Why hVIVO Shares Rose 6.09%
No new company announcement had been confirmed as the trigger at the time of writing. The gain appears to reflect growing confidence in the recovery outlined at the interim results on 15 September 2026.
The key Factor is visibility. hVIVO said its contracted order book more than doubled during the first half of 2026, following one of its best periods of new contract sales. That pipeline underpins management's expectation that second-half revenue will be roughly double the first-half level.
As the fourth quarter begins, investors are looking for signs that contracted studies are starting on schedule. Each week of smooth delivery adds weight to the full-year guidance, which may be encouraging buyers back into the stock.
Interim Results Recap
For the six months ended 30 June 2026, hVIVO reported revenue of £16.3 million, down from £24.2 million a year earlier. The adjusted EBITDA loss was £4.5 million, compared with an adjusted EBITDA of £3.0 million in the first half of 2025, reflecting lower utilisation while new studies were being contracted.
Cash stood at £13.0 million at 30 June 2026, compared with £14.3 million at the end of 2025.
Chief Executive Yamin 'Mo' Khan said the first half saw a clear improvement in commercial momentum, and the company now expects FY2026 group revenue of approximately £47 million. hVIVO expects positive adjusted EBITDA in the second half of 2026 and a low single-digit adjusted EBITDA loss for the full year.
The company also announced that Non-Executive Director Richard Cotton would be appointed Interim Chief Financial Officer.
A Broader Clinical Development Platform
In 2025, hVIVO completed the acquisitions of CRS in Mannheim and Kiel, Germany, and Cryostore. These deals give the group about 120 beds of clinical capacity in Germany and allow it to provide services from pre-clinical work through to Phase III trials. The company now operates under a single hVIVO brand, bringing consulting, trials and laboratories together.
At its recent Capital Markets Day, clients, investors and industry experts presented on the strength of the integrated Business model.
Why Investors Are Watching LSE:HVO
hVIVO is in focus because 2026 is heavily weighted toward the second half, making the coming months critical. Investors are watching for evidence that studies are starting on time, utilisation is rising in London and Germany, and cash is being preserved during the ramp-up.
A successful second half would support a return to growth in 2027 and could prompt a re-rating of the shares after a weak period.
Risks to Consider
The heavy second-half weighting means any study cancellation or delay could quickly affect full-year results, as happened in FY2025. Clinical trial timing is often outside the company's control. Cash has been falling, and the group is loss-making at the adjusted EBITDA level for the year. The broader contract research market has faced funding headwinds. AIM-listed healthcare stocks can also be volatile.
Outlook
The 6.09% rise on 7 October 2026 reflects increasing confidence that hVIVO's doubled order book will translate into a sharp second-half rebound. With full-year revenue guidance of about £47 million and an expected return to positive adjusted EBITDA in H2, LSE:HVO is entering a pivotal period. Delivery over the next quarter will determine whether the recovery story holds.






Please wait processing your request...